(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vacation destinations in America - 2Poll: 62% of Americans would oppose U.S. military action in Greenland
- 3Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 4Cocoa Prices Undercut Amid the Prospects of Abundant Supplies
- 5Dozens of hidden star streams found in the outskirts of our Milky Way galaxy
- Pick Your Favored method of transportation
- Explainer-Why are hepatitis B vaccines given to newborns?
- Eight arrested in joint Scotland and Spain gang raids
- 5 Instructive Toy Brands for Youngsters
- 10 Famous Frozen yogurt Flavors All over The Planet
- The Best Web-based Courses for Expertise Improvement
- Figure out How to Stay away from Normal Handshaking Missteps
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Two separate Israeli espionage cases uncover Iran-linked activities in Jerusalem, Ashkelon
